Moderate hypofractionation for prostate cancer: A user's guide

David I. Pryor*, Sandra L. Turner, Keen Hun Tai, Colin Tang, Giuseppe Sasso, Marcus Dreosti, Henry H. Woo, Lee Wilton, Jarad M. Martin

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Three large randomised controlled trials have been published in the last year demonstrating the non-inferiority of moderate hypofractionation compared to conventional fractionation for localised prostate cancer with respect to both disease control and late toxicity at 5 years. Furthermore, no clinically significant differences in patient-reported outcomes have emerged. More mature follow-up data are now also available from phase 2 studies confirming that moderate hypofractionation is associated with low rates of significant toxicity at 10 years. Moving forward it is likely that appropriate patient selection, integration of androgen deprivation and attention to optimising technique will play a more important role than modest differences in dose-fractionation schedules. Here we briefly review the evidence, discuss issues of patient selection and provide an approach to implementing moderately hypofractionated radiation therapy for prostate cancer in clinical practice.

Original languageEnglish
Pages (from-to)232-239
Number of pages8
JournalJournal of Medical Imaging and Radiation Oncology
Issue number2
Publication statusPublished - Apr 2018
Externally publishedYes


Dive into the research topics of 'Moderate hypofractionation for prostate cancer: A user's guide'. Together they form a unique fingerprint.

Cite this